William E. Steinkrauss
Geen lopende functies
Vermogen: 45 328 $ op 31-03-2024
Profiel
William E.
Steinkrauss worked as a Director-Technical Accounting & Reporting at OvaScience, Inc. from 2015 to 2016.
Prior to that, he was a Senior Manager-Technical Accounting at Cubist Pharmaceuticals LLC from 2012 to 2015.
Currently, he is the Chief Financial & Administrative Officer at Curis, Inc. starting from 2016.
Steinkrauss completed his undergraduate and graduate degrees from Boston College.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
CURIS, INC.
0.07% | 31-07-2023 | 4 170 ( 0.07% ) | 45 328 $ | 31-03-2024 |
Eerdere bekende functies van William E. Steinkrauss
Bedrijven | Functie | Einde |
---|---|---|
CURIS, INC. | Director of Finance/CFO | 05-08-2022 |
OvaScience, Inc.
OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA. | Corporate Officer/Principal | 01-08-2016 |
CUBIST PHARMACEUTICALS INC | Corporate Officer/Principal | 01-05-2015 |
Opleiding van William E. Steinkrauss
Boston College | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
CURIS, INC. | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
Cubist Pharmaceuticals LLC
Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA. | Health Technology |
OvaScience, Inc.
OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA. | Health Technology |